Decision Aid Web Tool for Kidney Cancer

Overseen By Samantha Sanger

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: NYU Langone Health

Disqualifiers: Stage IV cancer, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 2

40 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The objective of this study is to understand how patients make decisions about treating their kidney masses, and to identify key values and preferences for treating their kidney masses. The study team will develop a decision aid (DA) using the decision-analytic model to communicate personalized benefit/harm estimates to patients and promote patient-centered treatment of renal tumors.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications.

How does this treatment for kidney cancer differ from other treatments?

This treatment involves a decision aid web tool that helps patients with kidney cancer understand their options, focusing on the risks and benefits of surgical removal of small kidney masses. Unlike traditional treatments, this tool supports shared decision-making between patients and healthcare providers, making it unique in its approach to patient involvement. ^{1 2 3 4 5}

What data supports the effectiveness of the Decision Aid treatment for kidney cancer?

The research mentions the development and testing of a decision aid for small kidney masses, which suggests that the tool is designed to help patients understand their treatment options and make informed decisions. Additionally, an interactive data visualization tool was created to assist in decision-making for metastatic kidney cancer, indicating that such tools can enhance patient understanding and involvement in their treatment choices. ^{1 2 6 7 8}

Who Is on the Research Team?

Stella Kang, MD

Principal Investigator

NYU Langone Health

Are You a Good Fit for This Trial?

This trial is for men and women over 18 who are seeing a urologist at NYU for kidney tumors no larger than 4 cm. It's open to patients before and after surgery but not to those with stage IV cancer or anyone unable to consent.

Inclusion Criteria

I am 18 or older with a kidney tumor no larger than 4 cm.

You have appointments for regular medical check-ups at the NYU Urology Department.

Exclusion Criteria

Inability to provide informed consent

Vulnerable subjects will not be recruited

My cancer is at stage IV.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Counseling and Decision Aid

Participants use the decision aid (DA) to understand treatment options and make informed decisions about their kidney masses

1 day

1 visit (in-person)

Follow-up

Participants are monitored for decision satisfaction and shared decision making outcomes

1 day

1 visit (in-person)

What Are the Treatments Tested in This Trial?

Interventions

• Decision Aid (DA)

Trial Overview The study is testing a new web tool called Decision Aid (DA) against the usual information pamphlets given by hospitals. The DA aims to help kidney tumor patients understand their treatment options better.

How Is the Trial Designed?

Group I: Decision Aid (DA) Web Tool Experimental Treatment 1 Intervention

Group II: Institutional Pamphlet Active Control 1 Intervention

Who Is Running the Clinical Trial?

NYU Langone Health

Lead Sponsor

Trials

1,431

Recruited

838,000+

Published Research Related to This Trial

A patient decision aid (DA) for small kidney masses significantly improved patient knowledge about risks and treatment options, with scores increasing from 22.3% to 52.6% compared to standard educational materials.

The DA also encouraged more patients to discuss ablation as a treatment option, with 66.7% of DA users discussing it compared to only 18.2% of those using standard materials, indicating its effectiveness in promoting informed decision-making.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Development and Pilot Evaluation of a Decision Aid for Small Kidney Masses. Thomas, SA., Siriruchatanon, M., Albert, SL., et al.[2023]

A novel interactive visualization tool based on the IMDC criteria was developed and tested, showing that it can effectively help both lay-users and physicians estimate median survival times for patients with metastatic kidney cancer, using data from over 4,500 patients.

User testing revealed that the tool improved accuracy in prognosis calculations, especially for physicians, with 93% expressing interest in using the updated version clinically, indicating its potential for enhancing shared decision-making in cancer care.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. Shee, K., Pal, SK., Wells, JC., et al.[2021]

A study of 73 patients with small renal masses showed that while most had low decisional conflict after counseling, there was a significant lack of disease knowledge, indicating a need for improved patient education.

Patients experiencing higher decisional conflict reported lower satisfaction with their care and felt less involved in the decision-making process, highlighting the importance of effective communication and shared decision-making in treatment planning.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Decisional Quality in Patients With Small Renal Masses. Shirk, JD., Laviana, A., Lambrechts, S., et al.[2019]

A survey of 600 urologists in Germany revealed that while 98% are familiar with the EAU guidelines for managing renal cell cancer (RCC), follow-up practices often do not align with these recommendations, particularly regarding imaging protocols.

Only 84% of patients with metastatic RCC were offered systemic therapy, indicating a potential gap in treatment for this patient population despite the availability of established guidelines.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical Usage of Different Guidelines in Routine Management, Therapy and Follow-Up of Patients with Renal Cell Cancer in Germany. Spek, A., Szabados, B., Ziegelmüller, B., et al.[2017]

In a study of 81 patients with renal cell carcinoma, follow-up care was largely in line with guideline recommendations, with 72% of patients monitored by urologists using various imaging and diagnostic methods.

Only 12.5% of patients sought psycho-oncological support, indicating a potential gap in addressing the psychological needs of patients post-surgery.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparison of guideline recommendations with daily practice in patients with renal cell carcinoma. Schlenker, B., Seitz, M., Bader, MJ., et al.[2021]

A new evidence-based decision aid was developed to help patients with localized renal masses make informed choices between partial and radical nephrectomy, meeting high standards for quality and certification.

The decision aid was well-received by users, with 91% of respondents finding the language acceptable and 82% appreciating its length, indicating it is a useful tool for facilitating shared decision-making in urology.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Development and acceptability testing of a patient decision aid for individuals with localized renal masses considering surgical removal with partial or radical nephrectomy. McAlpine, K., Breau, RH., Stacey, D., et al.[2020]

In a study involving 382 newly diagnosed prostate cancer patients, those who used a decision aid (DA) were significantly more likely to choose active surveillance (AS) as a treatment option compared to those who did not use the DA (29% vs 16%).

Patients using the DA who were not eligible for AS opted for surgery more frequently than the control group (53% vs 35%), indicating that the DA influenced treatment decisions by helping patients clarify their preferences.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Differences in treatment choices between prostate cancer patients using a decision aid and patients receiving care as usual: results from a randomized controlled trial. Lamers, RED., Cuypers, M., de Vries, M., et al.[2022]

A study involving 160 participants, including patients with newly diagnosed breast, advanced-stage prostate, and advanced-stage lung cancer, found that a decision aid significantly improved understanding and involvement in treatment decisions for both patients and their caregivers.

The decision aid facilitated a shared decision-making process, leading to more satisfying treatment choices and highlighting the importance of caregiver involvement in understanding treatment options.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Capturing treatment decision making among patients with solid tumors and their caregivers. Jones, RA., Steeves, R., Ropka, ME., et al.[2021]

Citations

1. United States pubmed.ncbi.nlm.nih.gov

Development and Pilot Evaluation of a Decision Aid for Small Kidney Masses. [2023]

2. United States pubmed.ncbi.nlm.nih.gov

Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. [2021]

3. United States pubmed.ncbi.nlm.nih.gov

Decisional Quality in Patients With Small Renal Masses. [2019]

4. Switzerland pubmed.ncbi.nlm.nih.gov

Clinical Usage of Different Guidelines in Routine Management, Therapy and Follow-Up of Patients with Renal Cell Cancer in Germany. [2017]

5. England pubmed.ncbi.nlm.nih.gov

Comparison of guideline recommendations with daily practice in patients with renal cell carcinoma. [2021]

6. United States pubmed.ncbi.nlm.nih.gov

Development and acceptability testing of a patient decision aid for individuals with localized renal masses considering surgical removal with partial or radical nephrectomy. [2020]

7. Germany pubmed.ncbi.nlm.nih.gov

Differences in treatment choices between prostate cancer patients using a decision aid and patients receiving care as usual: results from a randomized controlled trial. [2022]

8. United States pubmed.ncbi.nlm.nih.gov

Capturing treatment decision making among patients with solid tumors and their caregivers. [2021]